The discovery of EML4-ALK fusion in 2007 as oncogenic driver in non-small-cell lung cancer (NSCLC) and next the identification of activating mutations in ALK gene in neuroblastoma made ALK one of the most extensively studied targets in the field of kinase inhibitor drug development (Chen et al. 2008; George et al. 2008; Janoueix-Lerosey et al. 2008; Mosse et al. 2008; Soda et al. 2007). This evidence concerns the gene EML4 and non-small cell lung carcinoma.